The effect of renal dysfunction on BNP, NT-proBNP, and their ratio

American Journal of Clinical Pathology

Volumn 133, Issue 1, 2010, Pages 14-23

  Srisawasdi, Pornpen ^a   Vanavanan, Somlak ^a   Charoenpanichkit, Charaslak ^a   Kroll, Martin H ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B natriuretic peptide; BNP; Estimated glomerular filtration rate; Heart disease; Left ventricular ejection fraction; N terminal proBNP; Natriuretic peptide; New York Heart Association class; NT proBNP; NT proBNP BNP ratio; Renal dysfunction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CREATININE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORAX PAIN;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEST PAIN; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; STROKE VOLUME;

EID: 73949104478     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP60HTPGIGFCNK     Document Type: Article

References (35)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
2. Omland T, Persson A, Ng L, et al. N-terminal pro B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918.
3. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
4. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRETIMI 23 substudy. J Am Coll Cardiol. 2004;44:335-339.
5. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point of care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-374.
6. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728-735.
7. Nielson LS, Svanegaard J, Klitgaard NA, et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail. 2004;6:63-70.
8. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
9. Kroll MH, Srisawasdi P. The clearance of BNP modeled using the NT-proBNP-BNP relationship. Biosystems. 2007;88:147-155.
10. Yeo K-TJ, Wu AHB, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338:107-115.
11. Rawlins ML, Own WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol. 2005;123:439-445.
12. Maack T. Receptors of natriuretic peptides. In: Laragh J, ed. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:833-840.
13. Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits: effect of the kidney, the natriuretic peptide clearance receptor, and peptides activity. J Pharmacol Exp Ther. 1999;289:976-980.
14. Koch AME, Rauh M, Zink S, et al. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr. 2006;95:805-809.
15. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11:239-245.
16. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-1517.
17. Stevenson LW, Nohria A, Meilniezuk L. Torrent or torment from the tubules? challenge of the cardiorenal connection [editorial]. J Am Coll Cardiol. 2005;45:2004-2007.
18. Spanaus KS, Kronenberg F, Ritz E, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem. 2007;53:1264-1272.
19. Myers GL, Miller WG, Coresh J, et al. Recommendation for improving serum creatinine measurement: a report from Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52:5-18.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
21. Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol. 2008;51:1874-1882.
22. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
23. Vanderheyden M, Bartunek J, Clacys G, et al. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem. 2006;39:640-645.
24. Mair J, Gerda F, Renate H, et al. Head-to-head comparison of B-type natriuretic peptide (BNP) and NT-proBNP in daily clinical practice. Int J Cardiol. 2008;124:244-246.
25. Hunt SA, Barker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104:2996-3007.
26. Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent "pancardiac" target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J. 2007;28:1678-1682.
27. Holmes SJ, Espiner EA, Richards AM, et al. Renal endocrine and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
28. McCullough PA, Due P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-579.
29. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46:610-620.
30. Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis dependent CRF. Am J Kidney Dis. 2004;44:420-428.
31. Mark PB, Stewart GA, Gansevoort RT, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant. 2006;21:402-410.
32. Kroll MH, Twomey PJ, Srisawasdi P. Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. Clin Chim Acta. 2007;380:197-202.
33. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
34. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol. 2005;95:948-954.
35. Wu AH. Serial testing of B-type natriuretic peptide and NT-proBNP for monitoring therapy of heart failure: the role of biological variation in the interpretation of results. Am Heart J. 2006;152:828-834.